Comparison of Dapagliflozin, Lobeglitazone, and Its Combination in Efficacy and Safety

NCT05915949 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

99

Enrollment

OTHER

Sponsor class

Conditions

Diabetes Type 2

Interventions

DRUG: Dapagliflozin 10mg Tab
DRUG: Lobeglitazone 0.5 mg
DRUG: Dapagliflozin + Lobeglitazone

Sponsor

Seoul National University Bundang Hospital